Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.

Mayuri P Kannan, Sarojini Sreeraman, Chaitanya S Somala, Raja Bs Kushwah, Saravanan K Mani, Vickram Sundaram, Anand Thirunavukarasou

Future medicinal chemistry 2023 May

filter terms:

Targeted protein degradation (TPD) aids in developing novel bifunctional small-molecule degraders and eliminates proteins of interest. The TPD approach shows promising results in oncological, neurogenerative, cardiovascular and gynecological drug development. We provide an overview of technology advancements in TPD, including molecular glues, proteolysis-targeting chimeras (PROTACs), lysosome-targeting chimeras, antibody-based PROTAC, GlueBody PROTAC, autophagy-targeting chimera, autophagosome-tethering compound, autophagy-targeting chimera and chaperone-mediated autophagy-based degraders. Here we discuss the development and evolution of the TPD field, the variety of proteins that PROTACs target and the biological repercussions of their degradation. We particularly highlight the recent improvements in TPD research that utilize autophagy or the endolysosomal pathway, which enables the targeting of undruggable targets.

Citation

Mayuri P Kannan, Sarojini Sreeraman, Chaitanya S Somala, Raja Bs Kushwah, Saravanan K Mani, Vickram Sundaram, Anand Thirunavukarasou. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets. Future medicinal chemistry. 2023 May;15(10):867-883